Study Title
APEC1621F: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Ensartinib in Patients With Tumors Harboring ALK or ROS1 Genomic Alterations
Protocol ID
APEC1621F
Disease (Sub Disease)
All paediatric cancer types
Diagnosis Stage
Relapsed/refractory
Location
WA
Sponsor
National Cancer Institute (NCI)
Collaborators
Children's Oncology Group
Links
Trial Status
Open
Sites
Perth Children's Hospital
Study Type
Treatment
Phase
Phase 2
Age Eligibility
12 Months to 21 Years
International registry ID's
NCT03213652
| Study Title | APEC1621F: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Ensartinib in Patients With Tumors Harboring ALK or ROS1 Genomic Alterations |
|---|---|
| Protocol ID | APEC1621F |
| Disease (Sub Disease) | All paediatric cancer types |
| Diagnosis Stage | Relapsed/refractory |
| Location | WA |
| Sponsor | National Cancer Institute (NCI) |
| Collaborators | Children's Oncology Group |
| Links | https://clinicaltrials.gov/ct2/show/NCT03213652 |
| Trial Status | Open |
| Trial Open Date | 17/04/2018 |
| Sites | Perth Children's Hospital |
| Study Type | Treatment |
| Phase | Phase 2 |
| Age Eligibility | 12 Months to 21 Years |
| International registry ID's | NCT03213652 |